Skip to content
Open access · CC-BY via OpenAlex

Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein

Claudio A. Hetz, René L. Vidal, Paulina Troncoso-Escudero

Neural Regeneration Research · 2021 · ▲ 3 citations

Abstract

Huntington’s disease (HD) is an inherited autosomal dominant neurodegenerative disorder characterized by the development of adult-onset motor dysfunction, psychiatric disturbances and intellectual decline. HD is associated with an expansion of CAG repeat sequence in the huntingtin gene (Htt). Exon 1 of Htt normally contains between 6 to 35 CAG repeats, whereas in patients affected with HD it contains more than 40 trinucleotides. The mutant Htt protein (mHtt) exhibits gain-of-toxic properties that cause neuronal dysfunction and death (Saudou and Humbert, 2016). Protein misfolding and aggregation is a common molecular feature of HD, suggesting that impairment in the buffer capacity of the proteostasis(definition) network contributes to the pathogenesis of the disease. Multiple studies in cell culture and animal models, in addition to the analysis of postmortem human tissue, have indicated that one of the main nodes of the proteostasis network affected in HD involves the function of the endoplasmic reticulum (Vidal et al., 2011). XBP1 is a master regulator of the unfolded protein response (UPR), the main adaptive pathway to cope with endoplasmic reticulum stress (Hetz et al., 2020). We previously reported that the genetic disruption of the transcription factor XBP1 delays disease progression and reduces protein aggregation in models of HD (Vidal et al., 2012), in addition to amyotrophic lateral sclerosis (ALS; Hetz et al., 2009), Parkinson´s disease (Valdes et al., 2014) and Alzheimer´s disease (Duran-Aniotz et al., 2017). To identify disease-modifier genes involved in the neuroprotective effects of XBP1 deficiency, we performed gene expression profiling from brain tissue of these animals. This unbiased screening uncovered insulin-like growth factor 2 (IGF2) as the major upregulated gene (García-Huerta et al., 2020). IGF2 is a member of the insulin-like peptide family, which includes IGF1 and insulin, having important roles in brain physiology and neurodegeneration. We studied the significance of IGF2 to HD and performed cell culture studies demonstrating that IGF2 expression reduces the load of intracellular aggregates of mHtt and a polyglutamine peptide (polyQ, a peptide made of 79 glutamines), which was associated with a decrease in the half-life of mHtt. Importantly, IGF2 treatment protected medium spiny neurons derived from HD patients, in addition to spinocerebellar ataxia 3 patients, the second most common polyQ disease. Our previous studies in XBP1 deficient mice suggested that the upregulation of autophagy(definition) explained part of the protection observed in HD and ALS models (Hetz et al., 2009; Vidal et al., 2012). However, the reduced protein aggregation observed in cells stimulated with IGF2 was independent of the activity of autophagy and the proteasome pathways, the two main routes for mHtt clearance (García-Huerta et al., 2020). Instead, we observed that IGF2 signaling enhanced the secretion of soluble polyglutamine peptide (polyQ) tract species through exosomes and microvesicles. To determine the signaling pathways downstream of the IGF2 receptor that control mHtt secretion, we determined the proteome changes upon stimulation with IGF2 by quantitative proteomics. This study revealed changes in actin dynamics, including several actin-binding proteins, Rho GTPases, among other factors. In fact, IGF2 treatment increased actin dynamics and Rac1 activity, a modulator of actin polarization, which mediated the release of polyQ into the extracellular space (Figure 1A).Figure 1: The new discovered function of IGF2 expression in HD models and its roles in brain physiology and in neuropathological conditions.(A) In cellular and preclinical models of HD, IGF2 decreases the intracellular load of mutant huntingtin via signaling through IGF2 receptor. IGF2 does not activate autophagy or the proteasome-mediated degradation, but instead causes actin cytoskeleton remodeling inducing mHtt secretion to the extracellular compartment. IGF2 gene therapy reduces mHtt levels, prevents neuronal loss, and improves motor behavior in preclinical models. (B) In humans, IGF2 levels are reduced in the brain and blood from HD patients, which might be associated with increase accumulation of mutant huntingtin, and an increase in neuronal degeneration. (C) Under physiological conditions, IGF2 has important functions in the hippocampus, mediating memory formation, consolidation and extinction, participates in adult hippocampal neurogenesis, and in synapses formation and spine maturation. We speculate that IGF2 treatment would have beneficial effects in aging, possibly prolonging life span of treated subjects. Under pathological conditions with IGF2 treatment, the overexpression of IGF2 has shown neuroprotective effects in Alzheimer’s disease, amyotrophic lateral sclerosis, Fragile X syndrome, and HD. AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; HD: Huntington’s disease; IGF2: insulin-like growth factor 2.To determine the significance of IGF2 to the progression of HD, we developed a gene therapy strategy to deliver IGF2 into the brain. Administration of IGF2 to the striatum resulted in a marked decrease in the levels of mHtt aggregation in three different animal models of HD. Finally, due to the dramatic effects of IGF2 on intracellular mHtt levels, we moved forward to explore possible changes in IGF2 levels in the brain and blood samples derived from HD patients. We observed a marked reduction of IGF2 protein levels in caudate-putamen samples when compared with healthy donors. Moreover, we evaluated the presence of IGF2 in peripheral blood mononuclear cells from HD patients. Although control samples presented a clear expression of IGF2, HD-derived blood cells showed an almost 70% decrease in IGF2 protein levels. Since IGF2 is a soluble secreted factor, we measure the amount of IGF2 in plasma from HD patients using ELISA, revealing a small but significant decrease of circulating IGF2 in plasma samples derived from

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.4103/1673-5374.303020
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Hetz, C.A., Vidal, R.L., &amp; Troncoso-Escudero, P. (2021). Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein. <em>Neural Regeneration Research</em>. https://doi.org/10.4103/1673-5374.303020
Vancouver
Hetz CA, Vidal RL, Troncoso-Escudero P. Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein. Neural Regeneration Research. 2021. doi:10.4103/1673-5374.303020.
BibTeX
@article{claudio2021Therap, title = {Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein}, author = {Claudio A. Hetz and René L. Vidal and Paulina Troncoso-Escudero}, journal = {Neural Regeneration Research}, year = {2021}, doi = {10.4103/1673-5374.303020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings

Cold Spring Harbor Perspectives in Biology 2011
Open access · OA

Huntington's Disease

▲ 249